Trial Profile
A Multicenter Non-randomized Phase II Study to Evaluate Nab-paclitaxel in Metastatic Breast Cancer Patients Failing a Solvent Based Taxane as (Neo-)Adjuvant Treatment (Tiffany).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms Tiffany
- 03 Nov 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 17 Aug 2011 New trial record